Ubiquitination/ Proteasome
Once the substrate protein is labeled, proteasome will bind to a polyubiquitin chain, allowing the degradation of the labeled protein. The polyubiquitinated target protein is then recognized and degraded by the 26S proteasome. Deubiquitinating enzymes (DUBs) reverse the process of ubiquitination by removing ubiquitin from its substrate protein. Dysregulation of the ubiquitin-proteasome system has been linked to cancer, diabetes, cardiovascular and neurodegenerative diseases etc.
-
A2614 Bortezomib (PS-341)24 CitationTarget: ProteasomeSummary: Proteasome Inhibitor
-
A1900 PSISummary: Proteasome inhibitor
-
A1903 E 64d4 CitationSummary: Cysteine protease inhibitor
-
A4393 Paclitaxel (Taxol)4 CitationTarget: Microtubules/TubulinsSummary: Antineoplastic agent
-
A1933 Carfilzomib (PR-171)10 CitationTarget: ProteasomeSummary: Proteasome inhibitor, epoxomicin analog
-
A1934 Oprozomib (ONX-0912)5 CitationSummary: Proteasome inhibitor
-
A8163 AM 1142 CitationTarget: ProteasomeSummary: 20S proteasome inhibitor
-
B1317 ML-323Target: Deubiquitinating enzymes (DUBs)Summary: USP1-UAF1 inhibitor
-
B1307 SJB3-019ATarget: USPSummary: Usp1 inhibitor
-
B1397 Trifluoperazine 2HClSummary: Dopamine D2 receptor inhibitor